{"title":"细胞因子信号模拟抑制因子作为自身免疫性脑炎的一种治疗方法。","authors":"Rahul Pandey, Marina Bakay, Hakon Hakonarson","doi":"10.1002/eji.70023","DOIUrl":null,"url":null,"abstract":"<p><p>Autoimmune encephalitis (AE) is a debilitating neurological condition characterized by the immune system's attack on neuronal cells, often leading to significant cognitive and neurological impairments. Autoantibodies, particularly those targeting N-methyl-D-aspartate receptors (NMDAR), are linked to the disease. Additionally, cytokine dysregulation has been associated with heightened inflammatory responses in AE. Early intervention is critical for favorable outcomes. Recent findings have underscored the importance of suppressor of cytokine signaling (SOCS) proteins, particularly SOCS1, in regulating cytokine signaling pathways and maintaining immune balance. SOCS1 mimetics in particular, designed to enhance SOCS1 activity, represent a novel therapeutic approach aimed at mitigating inflammation and promoting neuroprotection. This review underscores the intricate interactions between cytokines, SOCS family proteins, and the pathophysiology of AE, emphasizing the potential of SOCS1 mimetics and potentially other SOCS mimetics as a targeted treatment. This review also emphasizes the need for further research to validate the efficacy and safety of SOCS1 mimetics in clinical settings and their role in improving outcomes for patients with AE.</p>","PeriodicalId":165,"journal":{"name":"European Journal of Immunology","volume":"55 8","pages":"e70023"},"PeriodicalIF":3.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Suppressor of Cytokine Signaling Mimetics as a Therapeutic Approach in Autoimmune Encephalitis.\",\"authors\":\"Rahul Pandey, Marina Bakay, Hakon Hakonarson\",\"doi\":\"10.1002/eji.70023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Autoimmune encephalitis (AE) is a debilitating neurological condition characterized by the immune system's attack on neuronal cells, often leading to significant cognitive and neurological impairments. Autoantibodies, particularly those targeting N-methyl-D-aspartate receptors (NMDAR), are linked to the disease. Additionally, cytokine dysregulation has been associated with heightened inflammatory responses in AE. Early intervention is critical for favorable outcomes. Recent findings have underscored the importance of suppressor of cytokine signaling (SOCS) proteins, particularly SOCS1, in regulating cytokine signaling pathways and maintaining immune balance. SOCS1 mimetics in particular, designed to enhance SOCS1 activity, represent a novel therapeutic approach aimed at mitigating inflammation and promoting neuroprotection. This review underscores the intricate interactions between cytokines, SOCS family proteins, and the pathophysiology of AE, emphasizing the potential of SOCS1 mimetics and potentially other SOCS mimetics as a targeted treatment. This review also emphasizes the need for further research to validate the efficacy and safety of SOCS1 mimetics in clinical settings and their role in improving outcomes for patients with AE.</p>\",\"PeriodicalId\":165,\"journal\":{\"name\":\"European Journal of Immunology\",\"volume\":\"55 8\",\"pages\":\"e70023\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/eji.70023\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/eji.70023","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
自身免疫性脑炎(AE)是一种衰弱的神经系统疾病,其特征是免疫系统对神经元细胞的攻击,通常导致严重的认知和神经损伤。自身抗体,特别是针对n -甲基- d -天冬氨酸受体(NMDAR)的抗体,与该疾病有关。此外,细胞因子失调与AE的炎症反应升高有关。早期干预是获得良好结果的关键。最近的研究结果强调了细胞因子信号传导抑制蛋白(SOCS),特别是SOCS1在调节细胞因子信号传导途径和维持免疫平衡中的重要性。特别是SOCS1模拟物,旨在增强SOCS1活性,代表了一种新的治疗方法,旨在减轻炎症和促进神经保护。这篇综述强调了细胞因子、SOCS家族蛋白和AE病理生理之间复杂的相互作用,强调了SOCS1模拟物和其他SOCS模拟物作为靶向治疗的潜力。这篇综述还强调需要进一步的研究来验证SOCS1模拟物在临床环境中的有效性和安全性,以及它们在改善AE患者预后方面的作用。
Suppressor of Cytokine Signaling Mimetics as a Therapeutic Approach in Autoimmune Encephalitis.
Autoimmune encephalitis (AE) is a debilitating neurological condition characterized by the immune system's attack on neuronal cells, often leading to significant cognitive and neurological impairments. Autoantibodies, particularly those targeting N-methyl-D-aspartate receptors (NMDAR), are linked to the disease. Additionally, cytokine dysregulation has been associated with heightened inflammatory responses in AE. Early intervention is critical for favorable outcomes. Recent findings have underscored the importance of suppressor of cytokine signaling (SOCS) proteins, particularly SOCS1, in regulating cytokine signaling pathways and maintaining immune balance. SOCS1 mimetics in particular, designed to enhance SOCS1 activity, represent a novel therapeutic approach aimed at mitigating inflammation and promoting neuroprotection. This review underscores the intricate interactions between cytokines, SOCS family proteins, and the pathophysiology of AE, emphasizing the potential of SOCS1 mimetics and potentially other SOCS mimetics as a targeted treatment. This review also emphasizes the need for further research to validate the efficacy and safety of SOCS1 mimetics in clinical settings and their role in improving outcomes for patients with AE.
期刊介绍:
The European Journal of Immunology (EJI) is an official journal of EFIS. Established in 1971, EJI continues to serve the needs of the global immunology community covering basic, translational and clinical research, ranging from adaptive and innate immunity through to vaccines and immunotherapy, cancer, autoimmunity, allergy and more. Mechanistic insights and thought-provoking immunological findings are of interest, as are studies using the latest omics technologies. We offer fast track review for competitive situations, including recently scooped papers, format free submission, transparent and fair peer review and more as detailed in our policies.